Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001193125-22-120186
Filing Date
2022-04-26
Accepted
2022-04-26 16:00:55
Documents
12
Period of Report
2022-06-10

Document Format Files

Seq Description Document Type Size
1 DEF 14A d352792ddef14a.htm DEF 14A 533384
2 GRAPHIC g352792g00b03.jpg GRAPHIC 27373
3 GRAPHIC g352792g00b04.jpg GRAPHIC 23932
4 GRAPHIC g352792g00b05.jpg GRAPHIC 26108
5 GRAPHIC g352792g00b06.jpg GRAPHIC 30905
6 GRAPHIC g352792g00b07.jpg GRAPHIC 25516
7 GRAPHIC g352792g00b08.jpg GRAPHIC 22802
8 GRAPHIC g352792g00b09.jpg GRAPHIC 29777
9 GRAPHIC g352792g19u18.jpg GRAPHIC 730128
10 GRAPHIC g352792g36t07.jpg GRAPHIC 8204
11 GRAPHIC g352792g80y65.jpg GRAPHIC 623600
12 GRAPHIC g352792g94a81.jpg GRAPHIC 10985
  Complete submission text file 0001193125-22-120186.txt   2640936
Mailing Address 27 DRYDOCK AVENUE 8TH FLOOR BOSTON MA 02210
Business Address 27 DRYDOCK AVENUE 8TH FLOOR BOSTON MA 02210 (877) 442-5362
Ginkgo Bioworks Holdings, Inc. (Filer) CIK: 0001830214 (see all company filings)

EIN.: 872652913 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-40097 | Film No.: 22854215
SIC: 2836 Biological Products, (No Diagnostic Substances)